Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-23T18:05:02.555Z Has data issue: false hasContentIssue false
  • English
  • Français

Lack of Benefit With Combination Therapy for Clostridium difficile Infection

Published online by Cambridge University Press:  06 February 2017

Jessica C. Njoku ,
Trevor C. Van Schooneveld ,
Mark E. Rupp ,
Keith M. Olsen ,
Fang Qiu ,
Jane L. Meza  and
Elizabeth D. Hermsen
Jessica C. Njoku*
Affiliation:
Nebraska Medicine, Omaha, Nebraska Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, Nebraska
Trevor C. Van Schooneveld
Affiliation:
Nebraska Medicine, Omaha, Nebraska Department of Internal Medicine, Section of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska
Mark E. Rupp
Affiliation:
Nebraska Medicine, Omaha, Nebraska Department of Internal Medicine, Section of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska
Keith M. Olsen
Affiliation:
Nebraska Medicine, Omaha, Nebraska Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, Nebraska
Fang Qiu
Affiliation:
Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska
Jane L. Meza
Affiliation:
Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska
Elizabeth D. Hermsen
Affiliation:
Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, Nebraska Department of Global Population Health, Merck & Co., Inc., Kenilworth, New Jersey.
*
Address correspondence to Jessica C. Njoku, PharmD, Good Shepherd Medical Center, 700 E Marshall Ave, Longview, TX 75601 (chikajcn@gmail.com).
Get access Rights & Permissions [Opens in a new window]

Abstract

Limited data exist regarding combination therapy for Clostridium difficile infection (CDI). After adjusting for confounders in a cohort of patients with CDI and≥1 year old, combination therapy was not associated with significant differences in clinical outcomes, but it was associated with prolonged duration of therapy (1.22 days; 95% confidence interval, 1.03–1.44 days; P=.02).

Infect Control Hosp Epidemiol 2017;38:602–605

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 38 , Issue 5 , May 2017 , pp. 602 - 605
Copyright
© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Cohen, SH, Gerding, DN, Johnson, S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–455.CrossRefGoogle Scholar
2. Hensgens, MP, Goorhuis, A, Dekkers, OM, et al. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 2013;56:1108–1116.Google Scholar
3. Musher, DM, Aslam, S, Logan, N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586–1590.Google Scholar
4. Pelaez, T, Alcala, L, Alonso, R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46:1647–1650.Google Scholar
5. Diff Quik Chek Complete. TechLab website. http://www.techlab.com/diagnostics/c-difficile/ Published 2105. Accessed December 5, 2016.Google Scholar
6. Mullane, KM, Miller, MA, Weiss, K, et al. SL. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011;53:440–447.Google Scholar
7. Zar, FA, Bakkanagari, SR, Moorthi, KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307.Google Scholar
8. Li, R, Lu, L, Lin, Y, Wang, M, Liu, X. Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: a systematic review and meta-analysis. PLoS One 2015;10:e0137252.CrossRefGoogle ScholarPubMed
9. Bass, SN, Bauer, SR, Neuner, EA, Lam, SW. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. J Hosp Infect 2013;85:22–27.Google Scholar
10. Rokas, KEE, Johnson, JW, Beardsley, JR, et al. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis 2015;61:934–941.Google Scholar